Skip to main
QURE

uniQure (QURE) Stock Forecast & Price Target

uniQure (QURE) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

uniQure NV demonstrates a strong financial outlook driven by advancements in its gene therapy pipeline, particularly with the promising development of AMT-130 and AMT-191, which are positioned to address serious conditions like Huntington's and Fabry diseases, respectively. The recent shift in the potential launch timeline for AMT-130 indicates an increased valuation perspective and highlights the resilience of uniQure's multi-asset platform amidst ongoing regulatory considerations. Additionally, the company maintains a solid balance sheet and continues to execute successfully across its central nervous system pipeline, providing a strategic foundation for future growth and potential market expansions.

Bears say

uniQure NV faces significant financial challenges as it remains a clinical-stage company without any revenue-generating products, which has resulted in ongoing losses since its inception. Additionally, intensifying competition from existing and emerging therapies targeting similar disease indications is likely to hinder market penetration and affect pricing strategies. Furthermore, potential delays in clinical development, regulatory approvals, or commercialization timelines could exacerbate costs and prolong the path to bringing products to market, further complicating the company’s financial outlook.

uniQure (QURE) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of uniQure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About uniQure (QURE) Forecast

Analysts have given uniQure (QURE) a Buy based on their latest research and market trends.

According to 11 analysts, uniQure (QURE) has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

uniQure (QURE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.